Julijana Kristl

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1981791/publications.pdf

Version: 2024-02-01

61984 88630 5,103 87 43 70 citations h-index g-index papers 88 88 88 7396 times ranked docs citations citing authors all docs

#	Article	IF	Citations
1	Nanofibers with probiotics combination for treatment of periodontal disease. , 2022, , .		O
2	Preparation and characterization of innovative electrospun nanofibers loaded with pharmaceutically applicable ionic liquids. International Journal of Pharmaceutics, 2022, 615, 121510.	5.2	8
3	Influence of Excipient Composition on Survival of Vaginal Lactobacilli in Electrospun Nanofibers. Pharmaceutics, 2022, 14, 1155.	4.5	4
4	Nanotechnology-Based Drug Delivery to Improve the Therapeutic Benefits of NRF2 Modulators in Cancer Therapy. Antioxidants, 2021, 10, 685.	5.1	28
5	Treatment challenges and delivery systems in immunomodulation and probiotic therapies for periodontitis. Expert Opinion on Drug Delivery, 2021, 18, 1229-1244.	5.0	16
6	Challenges in nanofiber testing in vitro. , 2021, , .		0
7	Drug Delivery Strategies for Curcumin and Other Natural Nrf2 Modulators of Oxidative Stress-Related Diseases. Pharmaceutics, 2021, 13, 2137.	4.5	19
8	Engineering of Vaginal Lactobacilli to Express Fluorescent Proteins Enables the Analysis of Their Mixture in Nanofibers. International Journal of Molecular Sciences, 2021, 22, 13631.	4.1	7
9	Magnetic Resonance Methods as a Prognostic Tool for the Biorelevant Behavior of Xanthan Tablets. Molecules, 2020, 25, 5871.	3.8	1
10	Polyelectrolyte–surfactant–complex nanoparticles as a delivery platform for poorly soluble drugs: A case study of ibuprofen loaded cetylpyridinium-alginate system. International Journal of Pharmaceutics, 2020, 580, 119199.	5.2	15
11	Effects of Electrospinning on the Viability of Ten Species of Lactic Acid Bacteria in Poly(Ethylene) Tj ETQq1 1 0.78	34314 rgB	T Overlock 1
12	Effect of Solution Composition Variables on Electrospun Alginate Nanofibers: Response Surface Analysis. Polymers, 2019, 11, 692.	4.5	47
13	Dynamics of water and xanthan chains in hydrogels studied by NMR relaxometry and their influence on drug release. International Journal of Pharmaceutics, 2019, 563, 373-383.	5.2	25
14	Image-Based Investigation: Biorelevant Solubility of \hat{l}_{\pm} and \hat{l}_{3} Indomethacin. Analytical Chemistry, 2019, 91, 3997-4003.	6.5	17
15	Sustained release of antimicrobials from double-layer nanofiber mats for local treatment of periodontal disease, evaluated using a new micro flow-through apparatus. Journal of Controlled Release, 2019, 316, 223-235.	9.9	40
16	Development of electrospun nanofibers that enable high loading and long-term viability of probiotics. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 136, 108-119.	4.3	92
17	Combinations of nanovesicles and physical methods for enhanced transdermal delivery of a model hydrophilic drug. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 127, 387-397.	4.3	21
18	Influence of different classes of crosslinkers on alginate polyelectrolyte nanoparticle formation, thermodynamics and characteristics. Carbohydrate Polymers, 2018, 181, 93-102.	10.2	42

#	Article	IF	Citations
19	Nanofibers with Incorporated Autochthonous Bacteria as Potential Probiotics for Local Treatment of Periodontal Disease. Biomacromolecules, 2018, 19, 4299-4306.	5.4	53
20	Development of probiotic-loaded microcapsules for local delivery: Physical properties, cell release and growth. European Journal of Pharmaceutical Sciences, 2018, 121, 178-187.	4.0	29
21	Impact of PCL nanofiber mat structural properties on hydrophilic drug release and antibacterial activity on periodontal pathogens. European Journal of Pharmaceutical Sciences, 2018, 122, 347-358.	4.0	62
22	Effect of surface hydrophobicity of therapeutic protein loaded in polyelectrolyte nanoparticles on transepithelial permeability. Acta Pharmaceutica, 2018, 68, 275-293.	2.0	16
23	Application of miscibility analysis and determination of Soluplus solubility map for development of carvedilol-loaded nanofibers. International Journal of Pharmaceutics, 2017, 533, 445-454.	5.2	17
24	Development of medicated foams that combine incompatible hydrophilic and lipophilic drugs for psoriasis treatment. International Journal of Pharmaceutics, 2017, 524, 65-76.	5.2	11
25	Development of Cetylpyridinium-Alginate Nanoparticles: A Binding and Formulation Study. International Journal of Pharmaceutics, 2016, 511, 774-784.	5.2	13
26	Formulation and evaluation of chitosan/polyethylene oxide nanofibers loaded with metronidazole for local infections. European Journal of Pharmaceutical Sciences, 2016, 95, 152-160.	4.0	42
27	Long-Term Sustained Ciprofloxacin Release from PMMA and Hydrophilic Polymer Blended Nanofibers. Molecular Pharmaceutics, 2016, 13, 295-305.	4.6	80
28	Controlled Release of Ciprofloxacin from Core–Shell Nanofibers with Monolithic or Blended Core. Molecular Pharmaceutics, 2016, 13, 1393-1404.	4.6	82
29	The Influence of High Drug Loading in Xanthan Tablets and Media with Different Physiological pH and Ionic Strength on Swelling and Release. Molecular Pharmaceutics, 2016, 13, 1147-1157.	4.6	20
30	Electrospun polycaprolactone nanofibers as a potential oromucosal delivery system for poorly water-soluble drugs. European Journal of Pharmaceutical Sciences, 2015, 75, 101-113.	4.0	139
31	Critical attributes of nanofibers: Preparation, drug loading, and tissue regeneration. International Journal of Pharmaceutics, 2015, 484, 57-74.	5.2	182
32	Local delivery of resveratrol using polycaprolactone nanofibers for treatment of periodontal disease. Journal of Drug Delivery Science and Technology, 2015, 30, 408-416.	3.0	51
33	Stability and solubility of trans-resveratrol are strongly influenced by pH and temperature. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 93, 196-204.	4.3	230
34	Nanofiber diameter as a critical parameter affecting skin cell response. European Journal of Pharmaceutical Sciences, 2015, 66, 29-35.	4.0	53
35	Contribution of Nanotechnology to Improved Treatment of Periodontal Disease. Current Pharmaceutical Design, 2015, 21, 3257-3271.	1.9	59
36	Thermoresponsive polymers: Insights into decisive hydrogel characteristics, mechanisms of gelation, and promising biomedical applications. International Journal of Pharmaceutics, 2014, 472, 262-275.	5.2	182

#	Article	IF	Citations
37	Development and bioevaluation of nanofibers with blood-derived growth factors for dermal wound healing. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 64-74.	4.3	69
38	The impact of relative humidity during electrospinning on the morphology and mechanical properties of nanofibers. International Journal of Pharmaceutics, 2013, 456, 125-134.	5.2	225
39	The design trend in tissue-engineering scaffolds based on nanomechanical properties of individual electrospun nanofibers. International Journal of Pharmaceutics, 2013, 455, 338-347.	5.2	62
40	The topography of electrospun nanofibers and its impact on the growth and mobility of keratinocytes. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 84, 401-411.	4.3	75
41	Intracellular trafficking of solid lipid nanoparticles and their distribution between cells through tunneling nanotubes. European Journal of Pharmaceutical Sciences, 2013, 50, 139-148.	4.0	16
42	Targeting intracellular compartments by magnetic polymeric nanoparticles. European Journal of Pharmaceutical Sciences, 2013, 50, 130-138.	4.0	40
43	Physical characteristics of poly (vinyl alcohol) solutions in relation to electrospun nanofiber formation. European Polymer Journal, 2013, 49, 290-298.	5.4	55
44	Nanofibers and their biomedical use. Acta Pharmaceutica, 2013, 63, 295-304.	2.0	56
45	Interfacial rheology: An overview of measuring techniques and its role in dispersions and electrospinning. Acta Pharmaceutica, 2012, 62, 123-140.	2.0	60
46	Using quantitative magnetic resonance methods to understand better the gel-layer formation on polymer-matrix tablets. Expert Opinion on Drug Delivery, 2011, 8, 677-692.	5.0	17
47	The manufacturing techniques of drug-loaded polymeric nanoparticles from preformed polymers. Journal of Microencapsulation, 2011, 28, 323-335.	2.8	95
48	A novel fluorescent probe for more effective monitoring of nanosized drug delivery systems within the cells. International Journal of Pharmaceutics, 2011, 416, 384-393.	5.2	18
49	The control of biofilm formation by hydrodynamics of purified water in industrial distribution system. International Journal of Pharmaceutics, 2011, 405, 16-22.	5.2	12
50	The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. International Journal of Pharmaceutics, 2010, 390, 61-69.	5.2	245
51	Nanosized particles of orlistat with enhanced in vitro dissolution rate and lipase inhibition. International Journal of Pharmaceutics, 2010, 396, 149-155.	5.2	35
52	A new approach combining different MRI methods to provide detailed view on swelling dynamics of xanthan tablets influencing drug release at different pH and ionic strength. Journal of Controlled Release, 2010, 145, 247-256.	9.9	63
53	Hyperbranched poly(esteramides) as solubility enhancers for poorly water-soluble drug glimepiride. International Journal of Pharmaceutics, 2010, 396, 119-126.	5.2	35
54	Toxicological Aspects of Longâ€Term Treatment of Keratinocytes with ZnO and TiO ₂ Nanoparticles. Small, 2010, 6, 1908-1917.	10.0	186

#	Article	IF	CITATIONS
55	Effect of Free and in Poly(η-caprolactone) Nanoparticles Incorporated New Type 1 17β -Hydroxysteroid Dehydrogenase Inhibitors on Cancer Cells. Current Nanoscience, 2010, 6, 69-76.	1.2	5
56	Current view on nanosized solid lipid carriers for drug delivery to the skin. Journal of Biomedical Nanotechnology, 2010, 6, 529-42.	1.1	4
57	The reflection of the texture of swollen polymer matrix on the release of incorporated substance. E-Polymers, 2009, 9, .	3.0	0
58	Inactivation of harmful tumour-associated proteolysis by nanoparticulate system. International Journal of Pharmaceutics, 2009, 381, 106-112.	5.2	25
59	Advantages of celecoxib nanosuspension formulation and transformation into tablets. International Journal of Pharmaceutics, 2009, 376, 204-212.	5.2	152
60	Improvements of cellular stress response on resveratrol in liposomes. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 73, 253-259.	4.3	92
61	Flavonoids and cinnamic acid derivatives as inhibitors of $17\hat{l}^2$ -hydroxysteroid dehydrogenase type 1. Molecular and Cellular Endocrinology, 2009, 301, 229-234.	3.2	48
62	High celecoxib-loaded nanoparticles prepared by a vibrating nozzle device. Journal of Microencapsulation, 2009, 26, 748-759.	2.8	23
63	Influence of nanosized delivery systems with benzyl nicotinate and penetration enhancers on skin oxygenation. International Journal of Pharmaceutics, 2008, 359, 220-227.	5.2	33
64	Surface active stabilizer Tyloxapol in colloidal dispersions exerts cytostatic effects and apoptotic dismissal of cells. Toxicology and Applied Pharmacology, 2008, 232, 218-225.	2.8	26
65	A novel gene delivery system for stable transfection of thiopurine-S-methyltransferase gene in versatile cell types. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 69, 23-30.	4.3	13
66	Effect of calcium ions on the gelling and drug release characteristics of xanthan matrix tablets. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 69, 698-707.	4.3	45
67	Immunonanoparticlesâ€fâ^'â€fan effective tool to impair harmful proteolysis in invasive breast tumor cells. FEBS Journal, 2007, 274, 4416-4427.	4.7	22
68	Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. Journal of Controlled Release, 2007, 120, 18-26.	9.9	376
69	Influence of polymers on the bioavailability of microencapsulated celecoxib. Journal of Microencapsulation, 2007, 24, 621-633.	2.8	17
70	Intracellular Delivery of Cysteine Protease Inhibitor Cystatin by Polymeric Nanoparticles. Journal of Nanoscience and Nanotechnology, 2006, 6, 3087-3094.	0.9	10
71	Investigation of liposomes as carriers of sodium ascorbyl phosphate for cutaneous photoprotection. International Journal of Pharmaceutics, 2005, 291, 21-29.	5.2	59
72	Quantitative evaluation of polymer concentration profile during swelling of hydrophilic matrix tablets using H NMR and MRI methods. European Journal of Pharmaceutics and Biopharmaceutics, 2005, 59, 299-306.	4.3	94

#	Article	IF	Citations
73	Nanoscale polymer carriers to deliver chemotherapeutic agents to tumours. Expert Opinion on Biological Therapy, 2005, 5, 1557-1569.	3.1	50
74	Cystatin incorporated in poly(lactide-co-glycolide) nanoparticles: development and fundamental studies on preservation of its activity. European Journal of Pharmaceutical Sciences, 2004, 22, 357-364.	4.0	66
75	Poly(lactide-co-glycolide) nanoparticles as a carrier system for delivering cysteine protease inhibitor cystatin into tumor cells. Experimental Cell Research, 2004, 301, 223-231.	2.6	62
76	Skin oxygenation after topical application of liposome-entrapped benzyl nicotinate as measured by EPR oximetry in vivo: Influence of composition and size. AAPS PharmSci, 2003, 5, 19-27.	1.3	15
77	Effect of colloidal carriers on ascorbyl palmitate stability. European Journal of Pharmaceutical Sciences, 2003, 19, 181-189.	4.0	83
78	Interactions of solid lipid nanoparticles with model membranes and leukocytes studied by EPR. International Journal of Pharmaceutics, 2003, 256, 133-140.	5.2	35
79	Skin protection against ultraviolet induced free radicals with ascorbyl palmitate in microemulsions. European Journal of Pharmaceutics and Biopharmaceutics, 2003, 56, 59-66.	4.3	51
80	Network structure of cellulose ethers used in pharmaceutical applications during swelling and at equilibrium. Pharmaceutical Research, 2002, 19, 1084-1090.	3.5	83
81	Investigation of the state and dynamics of water in hydrogels of cellulose ethers by 1H NMR spectroscopy. AAPS PharmSciTech, 2002, 3, E36.	3.3	52
82	Improved skin oxygenation after benzyl nicotinate application in different carriers as measured by EPR oximetry in vivo. Journal of Controlled Release, 2001, 70, 203-211.	9.9	51
83	Optimisation of floating matrix tablets and evaluation of their gastric residence time. International Journal of Pharmaceutics, 2000, 195, 125-135.	5.2	205
84	Viscosity prediction of lipophilic semisolid emulsion systems by neural network modelling. International Journal of Pharmaceutics, 2000, 196, 37-50.	5.2	33
85	Influence of liposome bilayer fluidity on the transport of encapsulated substance into the skin as evaluated by EPR. Pharmaceutical Research, 1998, 15, 525-530.	3.5	62
86	Lipophilic semisolid emulsion systems: viscoelastic behaviour and prediction of physical stability by neural network modelling. International Journal of Pharmaceutics, 1998, 168, 243-254.	5.2	51
87	Molecular motion of drugs in hydrocolloids measured by electron paramagnetic resonance. Pharmaceutical Research, 1991, 08, 505-507.	3.5	8